Pharmaceutical Technology
NOVEMBER 19, 2023
ADCs continue to demonstrate efficacy across different tumor types, and their use is expected to expand across indications as more suitable target antigens are identified and new and better technologies emerge.
BioSpace
NOVEMBER 19, 2023
Successful drugs from Novo Nordisk and Eli Lilly are just the beginning of what one analyst says could be “the largest therapeutic class of drugs that the biopharma industry has ever seen.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
JAMA Internal Medicine
NOVEMBER 19, 2023
This Taiwanese cohort study evaluates the risk of bleeding and mortality after alteplase treatment for patients with acute ischemic stroke treated with non–vitamin K antagonist oral anticoagulants (NOACs) vs not treated with NOACs.
BioSpace
NOVEMBER 19, 2023
BioSpace takes a deep dive into five investigational therapeutic cancer vaccines that have recently shown efficacy in difficult-to-treat indications.
JAMA Internal Medicine
NOVEMBER 19, 2023
This cross-sectional study examines the provenance and clinical benefit of medicines that entered the French market between 2008 and 2018 using the Prescrire and Haute Autorité de Santé grading systems.
BioSpace
NOVEMBER 19, 2023
Vorasidenib decreased tumor volume by a mean of 2.5% every six months, compared to growth of 13.9% for placebo over the same time span. The candidate is also being tested in a regimen with Keytruda.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
NOVEMBER 19, 2023
Armed with a pipeline of obesity and diabetes hopefuls, Carmot Therapeutics joins the small group of biotechs to attempt a Nasdaq debut this year.
pharmaphorum
NOVEMBER 19, 2023
Lilly to invest $2.5bn for obesity, diabetes drug production Phil.
BioSpace
NOVEMBER 19, 2023
The new five-year deal will save the U.K.’s National Health Service an estimated £14 billion ($17.4 billion) and double the annual allowed growth in sales of branded medicines from 2% to 4% per year by 2027.
Drug Patent Watch
NOVEMBER 19, 2023
Annual Drug Patent Expirations for NUCYNTA+ER Nucynta Er is a drug marketed by Collegium Pharm Inc and is included in one NDA. It is available from one supplier. There are… The post New patent expiration for Collegium Pharm drug NUCYNTA ER appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
NOVEMBER 19, 2023
Bayer’s investigational factor XIa inhibitor asundexian was inferior to BMS' and Pfizer’s blockbuster blood thinner Eliquis (apixaban) in the Phase III OCEANIC-AF study.
Drug Patent Watch
NOVEMBER 19, 2023
Annual Drug Patent Expirations for HYSINGLA+ER Hysingla Er is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from one supplier. There are… The post New patent expiration for Purdue Pharma drug HYSINGLA ER appeared first on DrugPatentWatch - Make Better Decisions.
Pharmaceutical Commerce
NOVEMBER 19, 2023
CareMetx, a Hub services company that provides high-touch support to drive therapy initiation and adherence, conducted research involving over 100 participants, using both qualitative and quantitative methods. The primary aim was to understand how therapy manufacturers envision the future of Hubs.
Drug Patent Watch
NOVEMBER 19, 2023
Annual Drug Patent Expirations for OXYCONTIN Oxycontin is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from five suppliers. There are twenty-one… The post New patent expiration for Purdue Pharma drug OXYCONTIN appeared first on DrugPatentWatch - Make Better Decisions.
Pharmaceutical Commerce
NOVEMBER 19, 2023
In a recent study, CareMetx engaged with senior leadership at leading biopharmaceutical manufacturers, aiming to evaluate the optimal ways in which Hub data can enhance manufacturer support. These findings can serve as a valuable guide for manufacturers seeking insights on optimizing their utilization of Hub data.
Drug Patent Watch
NOVEMBER 19, 2023
Annual Drug Patent Expirations for OPANA+ER Opana Er is a drug marketed by Endo Pharms and is included in two NDAs. There are eleven patents protecting this drug and six… The post New patent expiration for Endo Pharms drug OPANA ER appeared first on DrugPatentWatch - Make Better Decisions.
Pharmaceutical Commerce
NOVEMBER 19, 2023
Among a variety of Hub vendors, what specific qualities distinguish differentiated support for drug manufacturers? To help answer this question, CareMetx conducted in-depth interviews and surveys with senior leadership at top manufacturers.
JAMA Internal Medicine
NOVEMBER 19, 2023
This case report describes a patient in their early 50s who presented with epigastric pain and jaundice and had significantly decreased heart rate after admission.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Commerce
NOVEMBER 19, 2023
Webinar Date/Time: Thu, Dec 14, 2023 11:00 AM EST
Drug Discovery World
NOVEMBER 19, 2023
The post High Content Imaging and Flow Cytometry in Drug Discovery 2023 appeared first on Drug Discovery World (DDW).
Drug Patent Watch
NOVEMBER 19, 2023
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Slovakia. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating… The post Which pharmaceutical companies have the most SPCs in Slovakia? appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
130 
Let's personalize your content